{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyOxZT6PzJTP+SYLGKIxwKvE",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/chitteti-syam/Gen-AI/blob/main/medical_analysis.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LcppmUkaGI5I",
        "outputId": "6f6443e3-bc2a-438d-af2b-684f3a0e029a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting biopython\n",
            "  Downloading biopython-1.85-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (13 kB)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.11/dist-packages (from biopython) (2.0.2)\n",
            "Downloading biopython-1.85-cp311-cp311-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (3.3 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m3.3/3.3 MB\u001b[0m \u001b[31m17.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: biopython\n",
            "Successfully installed biopython-1.85\n",
            "Requirement already satisfied: openai in /usr/local/lib/python3.11/dist-packages (1.72.0)\n",
            "Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.11/dist-packages (from openai) (4.9.0)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/local/lib/python3.11/dist-packages (from openai) (1.9.0)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.11/dist-packages (from openai) (0.28.1)\n",
            "Requirement already satisfied: jiter<1,>=0.4.0 in /usr/local/lib/python3.11/dist-packages (from openai) (0.9.0)\n",
            "Requirement already satisfied: pydantic<3,>=1.9.0 in /usr/local/lib/python3.11/dist-packages (from openai) (2.11.3)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.11/dist-packages (from openai) (1.3.1)\n",
            "Requirement already satisfied: tqdm>4 in /usr/local/lib/python3.11/dist-packages (from openai) (4.67.1)\n",
            "Requirement already satisfied: typing-extensions<5,>=4.11 in /usr/local/lib/python3.11/dist-packages (from openai) (4.13.1)\n",
            "Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.11/dist-packages (from anyio<5,>=3.5.0->openai) (3.10)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.11/dist-packages (from httpx<1,>=0.23.0->openai) (2025.1.31)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.11/dist-packages (from httpx<1,>=0.23.0->openai) (1.0.7)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.11/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.14.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.11/dist-packages (from pydantic<3,>=1.9.0->openai) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.33.1 in /usr/local/lib/python3.11/dist-packages (from pydantic<3,>=1.9.0->openai) (2.33.1)\n",
            "Requirement already satisfied: typing-inspection>=0.4.0 in /usr/local/lib/python3.11/dist-packages (from pydantic<3,>=1.9.0->openai) (0.4.0)\n"
          ]
        }
      ],
      "source": [
        "!pip install biopython\n",
        "!pip install openai  # Optional, if you want to summarize using GPT-based models\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from Bio import Entrez\n",
        "import openai\n",
        "import json\n"
      ],
      "metadata": {
        "id": "rZP0t5IMGWtP"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Set your Entrez API Key (if you have one)\n",
        "Entrez.email = \"your_email@example.com\"  # replace with your email\n",
        "\n",
        "# Set your OpenAI API Key (if using GPT-3/4 for summarization or Q&A)\n",
        "openai.api_key = \"your-openai-api-key\"\n"
      ],
      "metadata": {
        "id": "ZqcXMGimGaZa"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def search_pubmed(query, max_results=5):\n",
        "    handle = Entrez.esearch(db=\"pubmed\", term=query, retmax=max_results)\n",
        "    record = Entrez.read(handle)\n",
        "    id_list = record[\"IdList\"]\n",
        "\n",
        "    return id_list\n"
      ],
      "metadata": {
        "id": "ei9ZIpffGeQ0"
      },
      "execution_count": 4,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def fetch_article_details(id_list):\n",
        "    ids = \",\".join(id_list)\n",
        "    handle = Entrez.esummary(db=\"pubmed\", id=ids)\n",
        "    records = Entrez.read(handle)\n",
        "\n",
        "    articles = []\n",
        "    for record in records:\n",
        "        article = {\n",
        "            \"title\": record[\"Title\"],\n",
        "            \"source\": record[\"Source\"],\n",
        "            \"pub_date\": record[\"PubDate\"],\n",
        "            \"summary\": record[\"Summary\"]\n",
        "        }\n",
        "        articles.append(article)\n",
        "\n",
        "    return articles\n"
      ],
      "metadata": {
        "id": "Tta4u2KsGjBT"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from Bio import Entrez\n",
        "\n",
        "Entrez.email = \"your_email@example.com\"  # <- Replace with your real email\n",
        "\n",
        "def search_pubmed(query, max_results=5):\n",
        "    handle = Entrez.esearch(db=\"pubmed\", term=query, retmax=max_results)\n",
        "    record = Entrez.read(handle)\n",
        "    return record[\"IdList\"]\n",
        "\n",
        "def fetch_article_abstracts(id_list):\n",
        "    ids = \",\".join(id_list)\n",
        "    handle = Entrez.efetch(db=\"pubmed\", id=ids, rettype=\"abstract\", retmode=\"text\")\n",
        "    abstracts = handle.read()\n",
        "    return abstracts\n"
      ],
      "metadata": {
        "id": "4XmKn7_QGuMb"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "query = \"heart disease treatment\"\n",
        "id_list = search_pubmed(query, max_results=3)\n",
        "abstracts = fetch_article_abstracts(id_list)\n",
        "\n",
        "print(\"Fetched Abstracts:\\n\")\n",
        "print(abstracts)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mWpnXutNGxxT",
        "outputId": "0c31da04-5500-4ed2-f154-3a6273872985"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Fetched Abstracts:\n",
            "\n",
            "1. Respir Res. 2025 Apr 15;26(1):148. doi: 10.1186/s12931-025-03182-0.\n",
            "\n",
            "Altered maturation and activation state of circulating monocytes is associated \n",
            "with their enhanced recruitment in pulmonary arterial hypertension.\n",
            "\n",
            "Harper RL(#)(1)(2)(3), Zhou X(#)(4), Marciano DP(3)(4), Cao A(1)(2)(3), Wang \n",
            "L(1)(2)(3), Chen G(5), Adil MS(1)(2)(3), Zhou W(4), Maguire P(4), Deivanayagam \n",
            "S(1), Yu Q(5), Viswanathan V(6), Yang D(5), Martin M(1)(3), Isobe S(1)(2)(3), \n",
            "Otsuki S(1)(3), Burgess J(7), Inglis A(7), Kelley D(7), Del Rosario PA(7)(8), \n",
            "Hsi A(8), Haddad F(7)(8), Zamanian RT(7)(8), Boehm M(5), Snyder MP(3)(4), \n",
            "Rabinovitch M(9)(10)(11)(12).\n",
            "\n",
            "Author information:\n",
            "(1)Department of Pediatrics, Stanford University School of Medicine, CCSR-1215A, \n",
            "269 Campus Drive, Stanford, CA, 94305-5162, USA.\n",
            "(2)Basic Science and Engineering (BASE) Initiative, Betty Irene Moore Children's \n",
            "Heart Center, Lucile Packard Children's Hospital, Stanford, CA, 94305, USA.\n",
            "(3)Stanford Cardiovascular Institute, Stanford University School of Medicine, \n",
            "Stanford, CA, 94305, USA.\n",
            "(4)Department of Genetics, Stanford University School of Medicine, Stanford, CA, \n",
            "94305, USA.\n",
            "(5)National Heart, Lung & Blood Institute, National Institutes of Health, \n",
            "Bethesda, MD, 20800, USA.\n",
            "(6)Department of Radiation Oncology, Stanford University School of Medicine, \n",
            "Stanford, CA, 94305, USA.\n",
            "(7)Department of Medicine, Stanford University School of Medicine, Stanford, CA, \n",
            "94305, USA.\n",
            "(8)Vera Moulton Wall Center for Pulmonary Vascular Diseases, Stanford University \n",
            "School of Medicine, Stanford, CA, 94305, USA.\n",
            "(9)Department of Pediatrics, Stanford University School of Medicine, CCSR-1215A, \n",
            "269 Campus Drive, Stanford, CA, 94305-5162, USA. marlener@stanford.edu.\n",
            "(10)Basic Science and Engineering (BASE) Initiative, Betty Irene Moore \n",
            "Children's Heart Center, Lucile Packard Children's Hospital, Stanford, CA, \n",
            "94305, USA. marlener@stanford.edu.\n",
            "(11)Stanford Cardiovascular Institute, Stanford University School of Medicine, \n",
            "Stanford, CA, 94305, USA. marlener@stanford.edu.\n",
            "(12)Vera Moulton Wall Center for Pulmonary Vascular Diseases, Stanford \n",
            "University School of Medicine, Stanford, CA, 94305, USA. marlener@stanford.edu.\n",
            "(#)Contributed equally\n",
            "\n",
            "BACKGROUND: It is well-established that patients with pulmonary arterial \n",
            "hypertension (PAH) exhibit increased recruitment of circulating monocytes to \n",
            "their pulmonary arteries. However, it remains unclear whether these monocytes \n",
            "have intrinsic abnormalities that contribute to their recruitment and to PAH \n",
            "pathogenesis. This study aimed to characterize the gene expression profiles of \n",
            "circulating classical, intermediate, and non-classical monocytes and assess \n",
            "their maturation trajectory in patients with idiopathic (I) PAH compared to \n",
            "control subjects. Additionally, it sought to explore the relationship between \n",
            "the observed IPAH abnormalities and deficiencies in bone morphogenetic receptor \n",
            "2 (BMPR2), the most frequently mutated gene in PAH, and to assess adhesion and \n",
            "transendothelial migration, key processes in monocyte infiltration of pulmonary \n",
            "arteries.\n",
            "METHODS: Differentially expressed genes and maturation trajectories of \n",
            "circulating monocytes from patients with IPAH vs. control subjects were compared \n",
            "using single cell RNA sequencing (scRNAseq), followed by FACS analysis. \n",
            "Observations from IPAH and control cells were related to reduced BMPR2 using a \n",
            "THP1 monocyte cell line with BMPR2 reduced by siRNA as well as induced \n",
            "pluripotent stem cell (iPSC) derived monocytes (iMono) from hereditary (H) PAH \n",
            "patients with a BMPR2 mutation and monocytes from mice with Bmpr2 deleted \n",
            "(MON-Bmpr2-/-).\n",
            "RESULTS: Classical IPAH monocytes have decreased CD14 mRNA leading to a \n",
            "deviation in their maturation trajectory and early terminal fate, which is not \n",
            "rescued by cytokine treatment. Monocytes that evade early cell death show \n",
            "elevated STAT1, PPDPF and HLA-B, and an interferon (IFN) signature indicative of \n",
            "an altered activation state. A strong link between decreased BMPR2 and CD14 was \n",
            "observed in THP1 cells and in HPAH iMono with a BMPR2 mutation associated with \n",
            "STAT1 and IFN related genes, and in monocytes from MON-Bmpr2-/- mice. Increased \n",
            "adhesion to iPSC-derived endothelial cells (iECs) in HPAH-BMPR2 mutant iMono was \n",
            "associated with elevated ICAM1 expression. Enhanced transendothelial migration \n",
            "of these cells was associated with the reduction in endothelial VE-cadherin \n",
            "(CDH5).\n",
            "CONCLUSIONS: IPAH monocytes exhibit an altered activation state associated with \n",
            "reduced BMPR2 and CD14, along with elevated STAT1-IFN expression. These changes \n",
            "are linked to intrinsic functional abnormalities that contribute to the \n",
            "monocytes' increased propensity to invade the pulmonary circulation.\n",
            "\n",
            "© 2025. The Author(s).\n",
            "\n",
            "DOI: 10.1186/s12931-025-03182-0\n",
            "PMID: 40234964\n",
            "\n",
            "Conflict of interest statement: Declarations. Ethics approval and consent to \n",
            "participate: All human samples used were coded and all patients and controls \n",
            "signed an informed consent under protocols approved by the Institutional Review \n",
            "Board on Human Subjects in Medical Research at Stanford University. The Animal \n",
            "Care Committee at Stanford University approved all the experimental protocols \n",
            "used in this study in accordance with the guidelines of the American \n",
            "Physiological Society. Consent for publication: Not applicable. Competing \n",
            "interests: M.P.S. is a co-founder and scientific advisor for Crosshair \n",
            "Therapeutics, Exposomics, Filtricine, Fodsel, Iollo, InVu Health, January AI, \n",
            "Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, \n",
            "Personalis, Protos Biologics, Qbio, RTHM, SensOmics. M.P.S. serves as a \n",
            "scientific advisor for Abbratech, Applied Cognition, Enovone, Jupiter \n",
            "Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, \n",
            "TranscribeGlass, WndrHLTH, Yuvan Research. M.P.S. is a co-founder of NiMo \n",
            "Therapeutics. M.P.S. is an investor and scientific advisor of R42 and Swaza. \n",
            "M.P.S. is an investor in Repair Biotechnologies. The other authors declare no \n",
            "competing interest.\n",
            "\n",
            "\n",
            "2. J Cardiothorac Surg. 2025 Apr 16;20(1):197. doi: 10.1186/s13019-025-03434-6.\n",
            "\n",
            "Predictors of secondary revascularization after coronary artery bypass graft \n",
            "surgery and role of dual antiplatelet therapy.\n",
            "\n",
            "Ch IA(1)(2)(3), Nasir K(4), Chaudhry A(5)(6), Wu PT(5)(7), Siddique M(5)(6), \n",
            "Ullah R(5)(8), Tahirkheli M(5)(8), Qadar A(5)(8), Weitzel H(5), Jamal R(5), \n",
            "Tahirkheli N(5).\n",
            "\n",
            "Author information:\n",
            "(1)South Oklahoma Heart Research, 5200 E Interstate 240 Service Rd, Oklahoma \n",
            "City, OK, 73135, USA. babar_175@hotmail.com.\n",
            "(2)SSM Health Saint Anthony Hospital, 1000 N Lee Ave, Oklahoma City, OK, 3102, \n",
            "USA. babar_175@hotmail.com.\n",
            "(3)University of Oklahoma, 700 NE 13th Street, Oklahoma City, OK, 73104, USA. \n",
            "babar_175@hotmail.com.\n",
            "(4)Division of Cardiovascular Prevention and Wellness, Department of Cardiology, \n",
            "Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.\n",
            "(5)South Oklahoma Heart Research, 5200 E Interstate 240 Service Rd, Oklahoma \n",
            "City, OK, 73135, USA.\n",
            "(6)Armed Forces Institute of Cardiology, Rawalpindi, Pakistan.\n",
            "(7)Doctor of Physical Therapy Program, Southern California University of Health \n",
            "Sciences, Whittier, CA, 90604, USA.\n",
            "(8)University of Oklahoma, 700 NE 13th Street, Oklahoma City, OK, 73104, USA.\n",
            "\n",
            "BACKGROUND: Despite advancements in surgical techniques, interventional \n",
            "procedures, novel pharmacotherapies, and other contemporary treatments, patients \n",
            "after coronary artery bypass graft surgery (CABG) remain at risk for graft \n",
            "failure and progression of native vessel disease progression. Consequently, \n",
            "secondary revascularization is often required.\n",
            "METHODS: This is a retrospective observational study evaluating the incidence, \n",
            "trends, and predictors of revascularization after CABG surgery.\n",
            "RESULTS: Of 2,476 patients followed in this post-CABG study, 1458 patients \n",
            "received dual antiplatelet therapy (DAPT) compared to 1005 patients received \n",
            "aspirin monotherapy (AMT). The overall incidence of revascularization was \n",
            "significantly higher in the DAPT group (14.54%, 212 out of 1458) compared to the \n",
            "AMT group (7.07%, 71 out of 1005), with an odds ratio (OR) of 2.24 (95% CI: \n",
            "1.69-2.97, p < 0.001). 770 patients who received DAPT for six months or more \n",
            "after surgery were compared in sub-analysis and were noted to have significantly \n",
            "higher incidence of revascularization compared to AMT (22.08% vs. 6.96%; \n",
            "OR = 3.157, 95% CI: 2.734-4.940; p < 0.001). The binary regression model \n",
            "revealed that younger patients ( hazard ratio (HR) = 0.964, 95% CI: 0.95-0.97; \n",
            "p < 0.001), diabetics (HR = 1.50, 95% CI: 1.12-2.00, p = 0.007), patients who \n",
            "had fewer internal mammary artery grafts (HR = 0.54, 95% CI: 0.36-0.81, \n",
            "p = 0.003), and patients receiving DAPT of any duration after CABG (HR = 3.47, \n",
            "95% CI: 2.55-4.72, p < 0.001) were more likely to receive revascularization \n",
            "after CABG. The model, comprising these four predictors, was able to explain \n",
            "12.8% of the variance in post-CABG revascularization (Nagelkerke R² = 0.128; \n",
            "p < 0.001). The survival rates were 96.5% for the DAPT group and 92.0% for AMT \n",
            "(odds ratio (OR) = 0.421, 95% confidence interval (95% CI): 0.269-0.658; \n",
            "p < 0.001).\n",
            "CONCLUSION: Diabetes mellitus, younger age, fewer Internal mammary artery \n",
            "grafts, and the use of DAPT after CABG were strong predictors of the need for \n",
            "secondary revascularization.\n",
            "\n",
            "© 2025. The Author(s).\n",
            "\n",
            "DOI: 10.1186/s13019-025-03434-6\n",
            "PMID: 40234952\n",
            "\n",
            "Conflict of interest statement: Declarations. Conflict of interest/Disclosure: \n",
            "Dr Khurram Nasir MD: CONSULTING FEES/HONORARIA: Amgen Inc.(SIGNIFICANT), \n",
            "Esperion(MODEST), Novartis Corporation(MODEST), Novo Nordisk Inc.(SIGNIFICANT) \n",
            "SPEAKER'S BUREAU: Amgen Inc.(MODEST). All other authors: None. Ethics statement: \n",
            "This ethics statement affirms that the research adhered to the highest ethical \n",
            "standards and guidelines established by regulatory bodies. Informed consent was \n",
            "obtained from the participants, confidentiality and privacy of participant \n",
            "information were maintained, conflicts of interest are denied, high morals were \n",
            "upheld, data integrity and transparency were ensured, authorship criteria were \n",
            "outlined, and contributions were acknowledged appropriately.\n",
            "\n",
            "\n",
            "3. Orphanet J Rare Dis. 2025 Apr 15;20(1):180. doi: 10.1186/s13023-025-03695-3.\n",
            "\n",
            "Ultrasound-guided transbronchial biopsy in the diagnosis of fibrosing \n",
            "mediastinitis-associated pulmonary hypertension.\n",
            "\n",
            "Zhang Y(1), Song HX(2), Qi YJ(1), Sun NN(3), Huang ZS(1), Fu WL(2), Zhang J(4), \n",
            "Herth FJF(5), Fan Y(6).\n",
            "\n",
            "Author information:\n",
            "(1)Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical \n",
            "University, Chongqing, China.\n",
            "(2)Department of Pathology, Xinqiao Hospital, Third Military Medical University, \n",
            "Chongqing, China.\n",
            "(3)Chongqing Public Health Medical Center, Chongqing, China.\n",
            "(4)Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical \n",
            "University, Chongqing, China. jingzhang2016@163.com.\n",
            "(5)Department of Pneumology and Critical Care Medicine, Thoraxklinik, and \n",
            "Translational Lung Research Center Heidelberg, University of Heidelberg, \n",
            "Heidelberg, Germany. felix.herth@med.uni-heidelberg.de.\n",
            "(6)Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical \n",
            "University, Chongqing, China. fan_ye_sat@hotmail.com.\n",
            "\n",
            "BACKGROUND: Fibrosing mediastinitis is a rare benign disease frequently \n",
            "complicated by pulmonary hypertension. A definitive diagnosis for fibrosing \n",
            "mediastinitis-associated pulmonary hypertension (FM-PH) and its etiologies \n",
            "necessitates mediastinal biopsy and subsequent pathological assessment. \n",
            "Endobronchial ultrasound (EBUS)-guided transbronchial mediastinal cryobiopsy is \n",
            "a recently developed technique that provides diagnostic advantages over standard \n",
            "needle biopsy, particularly in benign mediastinal disorders. Nevertheless, their \n",
            "safety and efficacy in diagnosing FM-PH remain elusive.\n",
            "METHODS: We retrospectively studied patients with mediastinal lesion and \n",
            "pulmonary vascular compression who underwent both transbronchial needle \n",
            "aspiration and mediastinal cryobiopsy with EBUS guidance. Diagnostic yields of \n",
            "FM-PH and its etiologies, along with procedure-related adverse events, were \n",
            "analyzed. Immunohistochemical study was conducted to identify immunological \n",
            "properties of FM-PH.\n",
            "RESULTS: Of the 529 patients with mediastinal lesions, 80 exhibited pulmonary \n",
            "vessel compression, including 10 who were ultimately diagnosed with FM-PH \n",
            "following mediastinal biopsy and right heart catheterization. Cryobiopsy showed \n",
            "a higher diagnostic yield for FM-PH compared to needle aspiration (100% versus \n",
            "40%, p = 0.011). Disease etiologies included pneumoconiosis in 5 cases, \n",
            "tuberculosis in 3, and idiopathic FM-PH in the remaining 2. Cryobiopsy appeared \n",
            "to be superior to needle biopsy for etiological diagnosis, although this \n",
            "difference was not statistically significant (80% versus 60%, p = 0.628). \n",
            "Immunohistochemical analyses of cryosamples revealed mixed inflammatory \n",
            "infiltrates of B and T lymphocytes, as well as macrophages, surrounding or \n",
            "within FM-PH lesions. There was no significant bleeding or other complications.\n",
            "CONCLUSION: Transbronchial mediastinal cryobiopsy might be a safe and effective \n",
            "diagnostic tool for FM-PH, offering valuable information for personalized \n",
            "treatment.\n",
            "\n",
            "© 2025. The Author(s).\n",
            "\n",
            "DOI: 10.1186/s13023-025-03695-3\n",
            "PMID: 40234923\n",
            "\n",
            "Conflict of interest statement: Declarations. Ethics approval and consent to \n",
            "participate: This study was conducted ethically in accordance with the World \n",
            "Medical Association Declaration of Helsinki. The data collection was approved by \n",
            "the Ethics Committee of the Third Military Medical University (2019 - 062 - 01), \n",
            "and written informed consent was obtained from the patients for publication of \n",
            "this study and any accompanying images. Consent for publication: No consent was \n",
            "required from patients for publication. Competing interests: The authors have no \n",
            "conflicts of interest to declare.\n"
          ]
        }
      ]
    }
  ]
}